The anthracyclines: Will we ever find a better doxorubicin?

Seminars in Oncology

Volumn 19, Issue 6, 1992, Pages 670-686

  Weiss, Raymond B ^a,b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' DEAMINO 2' FLUORO 3' HYDROXYDOXORUBICIN 14 PIMELATE; 3' DEAMINO 3' MORPHOLINOOXAUNOMYCIN; 4' IODOESORUBICIN; 5 IMINODAUNORUBICIN; ACLARUBICIN; AMRUBICIN; ANTHRACYCLINE DERIVATIVE; CARUBICIN; DAUNORUBICIN; DETORUBICIN; DOXORUBICIN; EPIRUBICIN; ESORUBICIN; F 860191; FCE 21424; IDARUBICIN; MARCELLOMYCIN; N BENZYLDOXORUBICIN 14 VALERATE; NEMORUBICIN; PIRARUBICIN; RAZOXANE; RODORUBICIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALRUBICIN; ZORUBICIN;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER RESEARCH; CARDIOTOXICITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG INDICATION; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; INTRAVENOUS DRUG ADMINISTRATION; MULTIDRUG RESISTANCE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW;

ANIMAL; ANTIBIOTICS, ANTHRACYCLINE; CHEMISTRY, PHARMACEUTICAL; CLINICAL TRIALS; DAUNORUBICIN; DOXORUBICIN; DRUG EVALUATION; DRUGS, INVESTIGATIONAL; HEART DISEASES; HUMAN; NEOPLASMS;

EID: 0026714331     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (105)

1. “Daunomycin,” a new antibiotic of the rhodomycin group
2. Studi sperimentale sull'attivitá antineoplastica del nuovo antibiotico daunomicina
3. Rubidomycin: A new antibiotic with cytostatic properties
4. Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia
5. Accidents cardiaques observés au cours des traitements parla rubidomycine
6. Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius
7. Adriamycin (NSC-123,127): A new antibiotic with antitumor activity
8. Foreward
9. Clinical evaluation of adriamycin, a new antitumour antibiotic
10. Adriamycin—An antitumor antibiotic in the treatment of neoplastic diseases
11. Daunorubicin treatment of adult solid tumors
12. Synthesis and antitumor activity of 4-demethoxydaunorubicin, 4-demethoxy-7,9-diepidaunorubicin, and their β anomers
13. Idarubicin (4-demethoxydaunorubicin). A preliminary overview of preclinical and clinical studies
14. Phase II study of idarubicin given orally in the treatment of anthracycline-naive advanced breast cancer patients
15. A third anthracycline for acute leukemia
16. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia
17. Comparative evaluation of intensive post-remission therapy with different dose schedules of ara-C in adults with acute myeloid leukemia (AML). Initial reports of a CALGB phase III study
18. A prospective randomized trial of doxorubicin versus idarubicin in the treatment of advanced breast cancer
19. A phase II study of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer
20. Phase II trial of idarubicin (4-demethoxydaunorubicin) in advanced breast cancer
21. Bioavailability and pharmacology of oral idarubicin
22. Phase II study of oral idarubicin in favorable histology non-Hodgkin's lymphoma
23. Adriamycin (NSC-123127): New chemical developments and analogs
24. The effectiveness of the anthracycline analog 4′-epidoxorubicin in the treatment of experimental tumors: A review
25. Preliminary phase I study of 4′-epiadriamycin
26. Metabolism of 4′-modified analogs of doxorubicin. Unique glucuronidation pathway for 4′-epidoxorubicin
27. Epirubicin: A review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue
28. Current status of epirubicin (Farmorubicin) in the treatment of solid tumors
29. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide fluorouracil and either doxorubicin or epirubicin
30. Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v. fluorouracil, doxorubicin, and cyclo-phosphamide in advanced breast cancer: An Italian multi-centre trial
31. A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer
32. Epirubicin cardiotoxicity: A study of 135 patients with advanced breast cancer
33. Cardiac morphologic and functional changes induced by epirubicin chemotherapy
34. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer
35. Distant recurrence in breast cancer. Survival expectations and first choice of chemotherapy regimen
36. A phase I–II study of intensive-dose adriamycin for advanced breast cancer
37. 2) epirubicin
38. High-dose epirubicin (EPI) as initial therapy for advanced breast cancer
39. Epirubicin at four different dose levels in metastatic breast cancer. A randomized trial
40. Tetrahydropyranyl derivatives of daunomycin and adriamycin
41. 4′-O-tetrahydropyranyl-adriamycin as a potential new antitumor agent
42. Low heart and skin toxicity of tetrahydropyranyl derivative of adriamycin (THP-ADM) as observed by electron and light microscopy
43. (2″-R)-4′-O-tetra-hydropyranyladriamycin, a new anthracycline derivative; its effectiveness in lymphoid malignancies
44. Pirarubicin in advanced breast cancer: A French cooperative phase II study
45. Phase II study of THP-adriamycin (pirarubicin) and DTIC in advanced soft tissue sarcomas
46. Pirarubicin in combination chemotherapy for metastatic breast cancer
47. Clinical study of rubidazone (22 050 R.P.), a new daunorubicin-derived compound, in 170 patients with acute leukemia and other malignancies
48. Chemical and biological characterization of 4′-iodo-4′-deoxydoxorubicin
49. Evaluation of cardiotoxicity of a new anthracycline derivative: 4′ -deoxy-4′ -iodo-doxorubicin
50. Pharmacology and clinical toxicity of 4′-iodo-4′-deoxydoxorubicin: An example of successful application of pharmacokinetics to dose escalation in phase I trials
51. Activity and toxicity of 4′-iodo-4′deoxydoxorubicin in patients with advanced breast cancer
52. Phase II studies of 4′-iodo-4′-deoxydoxorubicin in advanced non-small cell lung, colon and breast cancers
53. N-trifluoroacetyladriamycin-14-valerate, an analog with greater experimental antitumor activity and less toxicity than adriamycin
54. Initial clinical evaluation of N-trifluoroacetyladriamycin-14-valerate (AD-32), an adriamycin analog
55. Initial clinical pharmacology of intravesical (ive) AD 32
56. Multidrug resistance
57. Pharmacological and physiochemical properties of a new anthracycline with potent antileukemic activity
58. New biosynthetic anthracyclines related to barminomycins incorporating barbituates in their moiety
59. Murine cardiotoxicity assay of the mechanistically novel adriamycin analog, N-benzyladriamycin-14-valerate (AD-198)
60. The cellular and biochemical pharmacology of the methoxymorpholino derivative of doxorubicin, FCE 23762
61. Phase I and pharmacokinetic study of SM-5887, a new anthracycline derivative
62. A fluorine-containing anthracycline (ME 2303) as a new antitumor agent against murine and human tumors and their multidrug-resistant sublines
63. Phase I clinical and pharmacokinetic study of ME 2303, a fluorine-containing anthracycline
64. MX2, a morpholino anthracycline, as a new antitumor agent against drug-sensitive and multidrug-resistant human and murine tumor cells
65. Phase I clinical study of MX2 (KRN 8602)
66. Phase I studies of rodorubicin single bolus and daily times five, once every three weeks in patients with advanced solid tumors
67. Estimation of the cardiotoxicity of N-1-leucyldoxorubicin from in vivo and ex vivo data in mice
68. Leurubicin (LEU-DOX), a prodrug of doxorubicin (DOX): Results of an ARTAC phase I clinical and pharmacokinetic study
69. Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer
70. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: A Southwest Oncology Group study
71. Liposomes as carriers of antitumor agents: Toward a clinical reality
72. Antitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: Phase II study
73. Phase I clinical trial of liposomal daunorubicin (daunoxome) in advanced malignancies
74. Use of anionic liposomes for the reduction of chronic doxorubicin-induced cardiotoxicity
75. Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation
76. Phase I/II study of liposome encapsulated doxorubicin (TLC-D99) in non small cell lung (NSCLC)
77. Phase I and comparative pharmacokinetic study of liposome-encapsulated doxorubicin
78. Phase II study of liposomal doxorubicin (TLCD99) in metastatic breast cancer
79. Adriamycin-induced free radical formation in the perfused rat heart:Implications for cardiotoxicity
80. Doxorubicin (Adriamycin): A critical review of free radical-dependent mechanisms of cytotoxicity
81. Antitumour activity in a series of bisdiketopiperazines
82. Phase I study of ICRF-187 using a daily for 3 days schedule
83. Prevention of the cardiotoxic effects of adriamycin and daunomycin in the isolated dog heart
84. Modification of some of the toxic effects of daunomycin (NSC-82,151) by pretreatment with the antineoplastic agent ICRF 159 (NSC-129,943)
85. Reduction of daunorubicin lethality and myocardial cellular alterations by pretreatment with ICRF-187 in Syrian golden hamsters
86. Reduction of chronic doxorubicin cardiotoxicity in dogs by pretreatment with (±)-1,2, bis(3,5-dioxopiperazinyl-1-yl) propane (ICRF-187)
87. Reducing doxorubicin cardiotoxicity in the rat using deferred treatment with ADR-529
88. The protective activity of ICRF-187 against doxorubicin-induced cardiotoxicity in the rat
89. Effects of ICRF-187 on the cardiac and renal toxicity of epirubicin in spontaneously hypertensive rats
90. Synergistic activity of doxorubicin and the bis-dioxopiperazine (+)-1,2 bis (3,5-dioxopiperazinyl-1-yl) propane (ICRF 187) against the murine sarcoma S180 cell line
91. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer
92. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer
93. Prevention of adriamycin cardiomyopathy with dexrazoxane (ADR-529, ICRF-187)
94. Prevention of chronic adriamycin cardiotoxicity with the bisdioxopiperazine dexrazoxane (ICRF-187, ADR-529, Zinecard) in patients with advanced or metastatic breast carcinoma
95. Advanced small cell lung cancer treated with CAV (cyclophosphamide + adriamycin + vincristine) chemotherapy and the cardio-protective agent dexrazoxane (ADR-529), ICRF-187, Zinecard)
96. Delayed cardiac toxicity from anthracycline therapy
97. Late effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood
98. Long term survival after heart transplantation for doxorubicin induced cardio-myopathy
99. ICRF 197 A new agent for protecting against drug-induced cardiotoxicity
100. Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors
101. Reversal of adriamycin resistance by verapamil in human ovarian cancer
102. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients
103. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: Detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy
104. Drug resistance in malignant lymphoma: Experience with EPOCH chemotherapy
105. Bepridil in combination with anthracyclines to reverse anthracycline resistance in cancer patients